BioSpace News Archive

uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that eight data presentations, of which three are oral presentations, will be delivered at the International Society on Thrombosis and Haemostasis (ISTH) Virtual Congress

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced three oral presentations and nine poster presentations related to valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress being held July 17-21, 2021

Breckenridge Pharmaceutical, Inc. announces that it has signed a multi-product agreement with Welding GmbH & Co. under which Welding will develop, manufacture and supply pharmaceutical products for marketing, sale and distribution by Breckenridge.

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of an aggregate of 124,580 restricted stock units of Atara’s common stock to 35 newly hired employees and stock options to purchase an aggregate of 99,585 shares of Atara’s common stock to 12 such newly hired employees.

InMed Pharmaceuticals Inc., a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, announced that it has closed the previously announced private placement.

Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus, announced grants of stock options to three new employees to purchase an aggregate of 21,520 shares of the Company’s common stock with an exercise price of $3.82 per share, the closing price of Assembly Bio’s common stock on July 1, 2021.

SANUWAVE Health, Inc., a leading provider of next-generation wound care products has announced that as of July 2, 2021 the company’s shares will no longer be traded on the OTCQB due to failure to timely file quarterly financials with the Securities & Exchange Commission.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 80,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Nicox SA, an international ophthalmology company, announced that the last patient in the NCX 4251 Mississippi Phase 2b blepharitis clinical trial has now completed the two-week treatment phase as well as the required two-week follow up period.

ObsEva SA announced the presentation of clinical data from the PROLONG Phase 2a proof-of-concept study of ebopiprant, an oral prostaglandin F2alpha antagonist, for the treatment of spontaneous preterm labor at the Society for Reproductive Investigation 68th Annual Meeting, being held virtually and in Boston July 6 -9, 2021.